, Tracking Stock Market Picks
Enter Symbol:
Alexion Pharmaceuticals, Inc. (ALXN) [hlAlert]

up 2,151.26 %

Alexion Pharmaceuticals, Inc. (ALXN) rated Buy by FTN Equity Capital

Posted on: Thursday,  Mar 12, 2009  9:25 AM ET by FTN Equity Capital

FTN Equity Capital rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 03/12/2009, when the stock price was $7.99.
Since then, Alexion Pharmaceuticals, Inc. has gained 2151.27% as of 12/11/2015's recent price of $179.82.
If you would have followed this FTN Equity Capital 's recommendation on ALXN, you would have gained 2151.26% of your investment in 2465 days.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Having access to accurate and timely information is essential for success in today's marketplace. At FTN Equity Capital Markets, our focus is on providing thorough and objective research to our clients, empowering them to make the well-informed and educated decisions that help enhance their investment process. Our highly experienced team of analytical experts research, examine, and evaluate businesses in several markets, including consumer, health care, business and technology services, and financial service sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2009 9:25 AM Buy
as of 12/31/2009
1 Week up  74.19 %
1 Month up  86.05 %
3 Months up  89.55 %
1 YTD up  164.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy